APA (7th ed.) Citation

Edwards, K., Uruska, A., Duda-Sobczak, A., Zozulinska-Ziolkiewicz, D., & Lingvay, I. (2023, June). Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: A structured qualitative assessment. Therapeutic Advances in Endocrinology and Metabolism.

Chicago Style (17th ed.) Citation

Edwards, Khary, Aleksandra Uruska, Anna Duda-Sobczak, Dorota Zozulinska-Ziolkiewicz, and Ildiko Lingvay. "Patient-perceived Benefits and Risks of Off-label Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 1 Diabetes: A Structured Qualitative Assessment." Therapeutic Advances in Endocrinology and Metabolism Jun. 2023.

MLA (9th ed.) Citation

Edwards, Khary, et al. "Patient-perceived Benefits and Risks of Off-label Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 1 Diabetes: A Structured Qualitative Assessment." Therapeutic Advances in Endocrinology and Metabolism, Jun. 2023.